HSV Oral Reactivation in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01878279
Recruitment Status : Completed
First Posted : June 14, 2013
Last Update Posted : June 14, 2013
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center

Brief Summary:

In the proposed study, the investigators will carry out novel research to evaluate both symptomatic and asymptomatic daily oral herpes simplex virus (HSV) shedding rates and copy number in children with and without HIV.

Study Objectives:

  1. To evaluate the frequency of oral HSV reactivation in HIV-infected and uninfected children

    Secondary Objectives:

  2. To determine the acceptability of performing daily oral swabs in children age 3-12

Condition or disease Intervention/treatment
HSV-1 HIV Other: Underlying medical illness

Study Type : Observational
Actual Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Longitudinal Study to Evaluate the Frequency of HSV-1 Oral Reactivation in Children in Dar es Salaam, Tanzania
Study Start Date : September 2008
Actual Primary Completion Date : July 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort Intervention/treatment
HIV negative
HIV positive
HIV positive children in care
Other: Underlying medical illness

Primary Outcome Measures :
  1. HSV detection rate [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. HSV copy number [ Time Frame: 14 days ]

Other Outcome Measures:
  1. compliance with daily swabs [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
For this Pilot study, we will enroll 20 HIV-infected and 10 HIV-uninfected children

Inclusion Criteria:

  • age > 3 and ≤12 years old
  • parental/guardian consent and children's assent must be obtained and participants and parent/guardian must be able to comply with study procedures
  • For HIV-infected group: Positive HIV serology by either ELISA x 2, ELISA + WB or PCR testing

Exclusion Criteria:

  • age <3 and > 12 years old
  • Acute illness which by opinion of the investigator makes enrollment in the trial unfeasible (including active tuberculosis, malaria or other opportunistic infection requiring treatment)
  • co-enrollment in other therapeutic/intervention trials (observational trial enrollment is permitted).
  • Stable co-administration of other medications is permitted (e.g. bactrim)
  • For HIV-infected children; receiving or eligible for antiretroviral (ART) therapy by local standards

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01878279

Dar es Salaam, Tanzania
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Principal Investigator: Richard Zuckerman, MD, MPH Dartmouth-Hitchcock Medical Center